GlassScriptPhysician profile
Charles Calais
NPI 1831416197
$4,981.85
in general payments reported to CMS, 2019-2025
23 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $262 · 2022: $491 · 2023: $1,256 · 2024: $1,893 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,196 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,195.66 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $790.20 | 2022-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $690.77 | 2022-2025 | Airsupra, Tezspire, Fasenra |
| Sanofi-Aventis U.S. LLC | $606.61 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $433.70 | 2021-2023 | Dupixent |
| Genentech USA, INC. | $422.38 | 2023-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $346.54 | 2023-2025 | Cuvitru, Takhzyro, Glassia |
| Genzyme Corporation | $312.23 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $281.57 | 2024-2025 | |
| Grifols USA, LLC | $192.88 | 2023-2025 | Xembify |
| Pfizer INC. | $147.72 | 2022-2023 | |
| Alk-Abello, INC | $143.19 | 2022-2025 | Odactra, Grastek, Ragwitek |
| Blueprint Medicines Corporation | $121.49 | 2025 | Ayvakit |
| Amgen INC. | $73.89 | 2024-2025 | Tezspire |
| Kaleo, INC. | $65.36 | 2022-2023 | Auvi-Q |
| Organon LLC | $61.86 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $60.63 | 2024 | |
| Greer Laboratories, INC. | $51.45 | 2022-2025 | Oralair |
| Csl Behring | $41.44 | 2024-2025 | Hizentra |
| Octapharma USA, INC. | $40.00 | 2024-2025 | Octagam Immune Globulin (Human), Cutaquig |
| Aimmune Therapeutics, INC. | $31.38 | 2021-2022 | |
| Kedrion Biopharma, INC. | $26.54 | 2025 | Kedrab, Gammaked, Koate |
| Pharming Healthcare, INC. | $25.54 | 2025 | Ruconest |
| Merck Sharp & Dohme LLC | $14.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Calais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.